New CiPA Cardiac Ion Channel Cell Lines and Assays for In Vitro Proarrhythmia Risk Assessment. Japanese Safety Pharmacology Society Meeting, Tokyo, 2020
Using new In Vitro Cardiac Ion Channel Assays and In Silico Models to Predict Proarrhythmia Risk with Automated Patch Clamp. Biophysical Society Annual Meeting, San Diego, 2020
Identification of Novel Scorpion Venom Peptide Inhibitors of the Kv1.3 Ion Channel and their Potential as Drug Discovery Leads for Human T-Cell Mediated Disease. RSC Ion Channels Symposium, Cambridge, 2020
Identification of Novel Ion Channel Binders: TRPA1 Antagonist Case Study. RSC Ion Channels Symposium, Cambridge, 2020.
Development of an Impedance Based Screening Assay for Cardiac Safety and Cardiotoxicity Detection in Stem Cell derived Cardiomyocytes. Safety Pharmacology Society Annual Meeting, Barcelona, 2019
Predicting Cardiac Proarrhythmic Risk Exclusively Using Automated Patch Clamp Data. Safety Pharmacology Society Annual Meeting, Barcelona, 2019
Identification of novel ion-channel binders: TRPA1 antagonist case study. (Collaboration with Domainex). World Preclinical Congress (WPC), Boston, 2019
Metrion Biosciences: high quality ion channel drug discovery service provider. Milner Therapeutics Symposium, Cambridge, 2019
The development of a set of novel small molecule inhibitors of the Kv1.3 ion channel. Biotech Outsourcing Strategy (BOS) Basel, 2019
A drug discovery collaboration between Japanese pharma and a UK SME CRO successfully developed novel small molecule inhibitors of the Kv1.3 channel to treat autoimmune disease. The Best of Both Worlds: Innovation, Collaboration and Synergy between CROs and their Client Partners, Stevenage, 2018.
Identification of novel scorpion venom peptide inhibitors of the Kv1.3 ion channel and their potential as drug discovery leads for human T-cell mediated disease. ELRIG Drug Discovery, London, 2018.
New CiPA cardiac ion channel cell lines and assays for in vitro proarrhythmia risk assessment. Safety Pharmacology Society meeting, Washington DC, USA 2018.
Assessment of human induced pluripotent stem cell-derived cardiomyocytes for evaluating drug-induced arrhythmias with multi-electrode array. Safety Pharmacology Society meeting, Washington DC, USA 2018.
Functional characterisation of human iPSC-derived atrial cardiomyocytes. SelectBio Stem Cells and Antibodies in Drug Discovery, Cambridge, May 2018.
Refining in vitro QPatch cardiac ion channel QPatch and MEA iPSC cardiomyocyte assays for CiPA. SOT San Antonio 2018 poster Late Breaking 12: Safety Assessment: Pharmaceutical and Non-Pharmaceutical.
Development of Native and Stem Cell-Derived Electrophysiological Assays for Neurotoxicology Screening and Translational Drug Discovery. SPS Berlin 2017 poster 142.
Comprehensive Profiling of Axiogenesis Ventricular vCor.4U iPSC-Derived Cardiomyocytes – From Electrophysiology to Phenotypic Assays. SPS Berlin 2017 poster 175.
Differentiation and Validation of Human iPSC-Derived Atrial Cardiomyocytes. SPS Berlin 2017 poster 176.
Electrophysiological Characterisation of Cellular Dynamics International Ventricular iCell2 iPSC-Derived Cardiomyocytes. SPS Berlin 2017 poster 177.
Monitoring drug-induced cytotoxicity and hepatotoxicity using impedance. Advances in Cell Based Screening, Gothenburg, May 2017.
CiPA update: Refining in vitro cardiac ion channel assays, in silico models and iPSC cardiomyocyte reagents for improved proarrhythmia risk prediction. SPS Vancouver September 2016 poster 0100.
Human ventricular stem cell cardiomyocytes: validating in vitro assays and screening platforms for proarrhythmia risk prediction. SPS Vancouver September 2016 poster 0242.
Human stem cell-derived cardiomyocytes: in vitro assays and screening platforms for exploring ventricular and atrial phenotypes. SPS Vancouver September 2016 poster 0247.
Electrophysiological profiling of Axiogenesis CorV.4U iPSC-derived cardiomyocytes. Axiogenesis Workshop Cologne September 2016.
Profiling endogenous sodium channels in the ND7-23 neuroblastoma cell line: implications for use as a heterologous ion channel expression system and native tissue model suitable for automated patch clamp screening. Royal Society for Chemistry Ion Channel Symposium, March 2016.
Developing a package of in vitro human cardiac ion channel assays using automated patch clamp to predict clinical arrhythmia risk. SPS Prague September 2015.
Optimising a difficult Nav1.8 cell line assay for automated patch clamp screening. Ion Channel Retreat, Vancouver, 2015.
Validation of an impedance-based phenotypic screening assay able to detect multiple mechanisms of chronic cardiotoxicity in human stem cell-derived cardiomyocytes. Presentation by Marc Rogers, CSO Metrion Biosciences, Nanion technologies Exhibitor session, 2020 Biophysical Society meeting, San Diego USA.
M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential. Presentation from Metrion Biosciences’ external speaker series, Professor Nikita Gamper, University of Leeds, 5th February 2019.
In depth profiling of human iPSC cardiomyocytes: From electrophysiology to phenotypic assays. Presentation by Metrion Biosciences’ Said El Haou, Ncardia Workshop, Cologne, 29th November – 1st December 2017.
Therapeutic Potential of Activators of Two-Pore Domain Ion Channels. Presentation from Metrion Biosciences’ external speaker series, Professor Alistair Mathie, Medway School of Pharmacy, 13th October 2017.
Modulation of voltage-gated calcium channels in disease. Presentation from the Metrion Biosciences’ external speaker series, Professor Gary Stephens, University of Reading, 28th November 2016.